Falquet, Maryline https://orcid.org/0000-0002-5940-8583
El Ahanidi, Hajar
Gomez-Cadena, Alejandra
Su, Ziyang
Cornu, Anthony https://orcid.org/0009-0005-2477-0020
Wyss, Tania https://orcid.org/0000-0003-2641-0895
Kizil, Burak
Pick, Robert https://orcid.org/0000-0001-9785-8481
Falamaki, Katayoun
Wirapati, Pratyaksha https://orcid.org/0000-0002-0327-4686
Fiordi, Benedetta
Senoner, Isis
Maresca, Daniela Claudia https://orcid.org/0009-0008-4221-6375
Kallal, Neil https://orcid.org/0009-0001-4299-2699
Guedj, Danaé https://orcid.org/0009-0004-2539-6432
Kreutzfeldt, Mario https://orcid.org/0000-0003-0335-2733
Tille, Jean-Christophe
Leblond, Marine M.
Michaud, Katarzyna
Pesce, Silvia
Candiani, Simona
Golebski, Korneliusz
Dagher, Julien
Charrier, Melinda
Pressacco Brossier, Caroline
Grobet-Jeandin, Elisabeth
Marone, Romina https://orcid.org/0000-0003-1474-1689
Hugues, Stéphanie
Jeker, Lukas T. https://orcid.org/0000-0002-3359-8796
Verdeil, Grégory https://orcid.org/0000-0001-9445-8474
Merkler, Doron https://orcid.org/0000-0002-0247-2007
Marcenaro, Emanuela https://orcid.org/0000-0003-4103-7566
Scheiermann, Christoph https://orcid.org/0000-0002-9212-0995
Attaleb, Mohammed
Benamran, Daniel
Tsantoulis, Petros https://orcid.org/0000-0003-3613-6682
Ercolano, Giuseppe https://orcid.org/0000-0001-6026-2588
Trabanelli, Sara https://orcid.org/0000-0001-8648-1324
Jandus, Camilla https://orcid.org/0000-0002-7405-5747
Article History
Received: 19 February 2024
Accepted: 11 February 2026
First Online: 21 February 2026
Competing interests
: L.T.J. co-founder, holding equity of Cimeio Therapeutics AG (Cimeio). Cimeio board member. Sponsored research agreement with Cimeio. Inventor on granted patents and patent applications related to immune cell engineering and antibodies. Received speaker fees from Novartis. Paid consultant for Kyowa Kirin. No competing interests directly affecting this study. The other authors declare no conflicts of interest.